Liver Transplantation in France
- PMID: 30697904
- DOI: 10.1002/lt.25419
Liver Transplantation in France
Abstract
In France, the main indications for liver transplantation are hepatocellular carcinoma (HCC) and alcoholic cirrhosis. The number of candidates for decompensated hepatitis C virus-related cirrhosis has markedly decreased since the advent of direct-acting antiviral agents. Nonalcoholic steatohepatitis represents a lower proportion of candidates as compared with the United States. The main source of donors is donation after brain death, but the program of transplantation using donation after circulatory death is growing with excellent results. The deceased donation rate was 28.8 per million people in 2017, which has increased over the last few years. Adult-to-adult living donor liver transplantation has been almost completely abandoned. Donors are allocated on a national basis, and there is no longer local or regional priority. In patients with decompensated cirrhosis, prioritization is based on the Model for End-Stage Liver Disease (MELD) score. The distance between the donor and the recipient is taken into account according to an original gravity model. In patients with HCC, prioritization depends on the alfa-fetoprotein (AFP) score, the MELD score, and waiting time. Only patients with HCC tumor-node-metastasis ≥2 and AFP score ≤2 are eligible for the HCC score. A list of MELD exceptions, consisting of uncommon complications where mortality risk is not adequately predicted by the MELD score and conditions other than cirrhosis, has been established. MELD exceptions must be individually validated by a college of experts mandated by the French Regulatory Agency of Transplantation (Agence de la Biomédecine). The most common MELD exception is refractory ascites with a low MELD score. A major challenge is to reduce the rate of refusal of donation through information campaigns.
Copyright © 2019 by the American Association for the Study of Liver Diseases.
Similar articles
-
Model for end-stage liver disease exceptions in the context of the French model for end-stage liver disease score-based liver allocation system.Liver Transpl. 2011 Oct;17(10):1137-51. doi: 10.1002/lt.22363. Liver Transpl. 2011. PMID: 21695771 Review.
-
A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.J Hepatol. 2014 Feb;60(2):290-7. doi: 10.1016/j.jhep.2013.10.010. Epub 2013 Oct 23. J Hepatol. 2014. PMID: 24161408
-
MELDEQ : An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma.Liver Transpl. 2015 May;21(5):612-22. doi: 10.1002/lt.24098. Epub 2015 Apr 15. Liver Transpl. 2015. PMID: 25694099
-
Are there better guidelines for allocation in liver transplantation? A novel score targeting justice and utility in the model for end-stage liver disease era.Ann Surg. 2011 Nov;254(5):745-53; discussion 753. doi: 10.1097/SLA.0b013e3182365081. Ann Surg. 2011. PMID: 22042468
-
Current Status of Simultaneous Liver-Kidney Transplantation in the United States.Liver Transpl. 2019 May;25(5):797-806. doi: 10.1002/lt.25444. Epub 2019 Apr 3. Liver Transpl. 2019. PMID: 30861294 Review.
Cited by
-
Risk assessment criteria in liver transplantation for hepatocellular carcinoma: proposal to improve transplant oncology.Hepat Oncol. 2020 Jul 24;7(3):HEP26. doi: 10.2217/hep-2020-0003. Hepat Oncol. 2020. PMID: 32774836 Free PMC article. Review.
-
Transplant Oncology: An Evolving Field in Cancer Care.Cancers (Basel). 2021 Sep 29;13(19):4911. doi: 10.3390/cancers13194911. Cancers (Basel). 2021. PMID: 34638395 Free PMC article. Review.
-
Liver Transplantation for Hepatocellular Carcinoma: How Should We Improve the Thresholds?Cancers (Basel). 2022 Jan 14;14(2):419. doi: 10.3390/cancers14020419. Cancers (Basel). 2022. PMID: 35053580 Free PMC article. Review.
-
Non-transplantable recurrence after percutaneous thermal ablation of ≤3-cm HCC: Predictors and implications for treatment allocation.Hepatol Commun. 2022 Oct;6(10):2975-2987. doi: 10.1002/hep4.2063. Epub 2022 Aug 6. Hepatol Commun. 2022. PMID: 35932178 Free PMC article.
-
Management of Hepatocellular Carcinoma in Decompensated Cirrhotic Patients: A Comprehensive Overview.Cancers (Basel). 2023 Feb 18;15(4):1310. doi: 10.3390/cancers15041310. Cancers (Basel). 2023. PMID: 36831651 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical